These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27344208)

  • 1. Neurodegeneration in tauopathies and synucleinopathies.
    Foguem C; Kamsu-Foguem B
    Rev Neurol (Paris); 2016 Nov; 172(11):709-714. PubMed ID: 27344208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
    Hauw JJ; Hausser-Hauw C; Duyckaerts C
    Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic Spine Pathology in Neurodegenerative Diseases.
    Herms J; Dorostkar MM
    Annu Rev Pathol; 2016 May; 11():221-50. PubMed ID: 26907528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases.
    Cummings J
    Am J Geriatr Psychiatry; 2021 Apr; 29(4):375-383. PubMed ID: 32819825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
    Li W; Li JY
    Transl Neurodegener; 2024 Mar; 13(1):16. PubMed ID: 38528629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anatamopathological spectrum of tauopathies.
    Revesz T; Holton JL
    Mov Disord; 2003 Sep; 18 Suppl 6():S13-20. PubMed ID: 14502651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases.
    Arnold SE; Toledo JB; Appleby DH; Xie SX; Wang LS; Baek Y; Wolk DA; Lee EB; Miller BL; Lee VM; Trojanowski JQ
    J Comp Neurol; 2013 Dec; 521(18):4339-55. PubMed ID: 23881776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interface between tauopathies and synucleinopathies: a tale of two proteins.
    Galpern WR; Lang AE
    Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
    Lee VM; Giasson BI; Trojanowski JQ
    Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
    Krüger R; Müller T; Riess O
    J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
    Higashi S; Iseki E; Yamamoto R; Minegishi M; Hino H; Fujisawa K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Kosaka K; Arai H
    Brain Res; 2007 Dec; 1184():284-94. PubMed ID: 17963732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinsonism plus syndrome--a review.
    Mitra K; Gangopadhaya PK; Das SK
    Neurol India; 2003 Jun; 51(2):183-8. PubMed ID: 14570999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filamentous nerve cell inclusions in neurodegenerative diseases.
    Goedert M; Spillantini MG; Davies SW
    Curr Opin Neurobiol; 1998 Oct; 8(5):619-32. PubMed ID: 9811617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
    Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P
    Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.
    Josephs KA; Tsuboi Y; Cookson N; Watt H; Dickson DW
    Arch Neurol; 2004 Oct; 61(10):1579-84. PubMed ID: 15477512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valosin-containing protein immunoreactivity in tauopathies, synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease.
    Mori F; Tanji K; Toyoshima Y; Sasaki H; Yoshida M; Kakita A; Takahashi H; Wakabayashi K
    Neuropathology; 2013 Dec; 33(6):637-44. PubMed ID: 23782134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.